Effects of guitar accompaniment style within patient preferred live music on mood and pain with hospitalized patients on a solid organ transplant unit: A three group randomized pilot study

2017 ◽  
Vol 52 ◽  
pp. 32-40 ◽  
Author(s):  
Brenton Haack ◽  
Michael J. Silverman
Keyword(s):  
Pilot Study ◽  
Organ Transplant ◽  
Solid Organ Transplant ◽  
Hospitalized Patients ◽  
Solid Organ ◽  
Live Music

Baseline Quality of Life and Anxiety in Solid Organ Transplant Recipients: A Pilot Study

2006 ◽  
Vol 32 (12) ◽  
pp. 1480-1485 ◽  
Author(s):  
FIONA O'REILLY ◽  
CARMEN TRAYWICK ◽  
MICHELLE L. PENNIE ◽  
JOVONNE K. FOSTER ◽  
SUEPHY C. CHEN
Keyword(s):  
Quality Of Life ◽  
Pilot Study ◽  
Organ Transplant ◽  
Solid Organ Transplant ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Organ Transplant Recipients ◽  
Solid Organ Transplant Recipients

scholarly journals Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant Recipients

2021 ◽  
Author(s):  
Zachary A Yetmar ◽  
Elena Beam ◽  
John C O’Horo ◽  
Ravindra Ganesh ◽  
Dennis M Bierle ◽  
...  
Keyword(s):  
Emergency Department ◽  
Monoclonal Antibody ◽  
Emergency Department Visit ◽  
Organ Transplant ◽  
Solid Organ Transplant ◽  
Hospitalized Patients ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Organ Transplant Recipients ◽  
Solid Organ Transplant Recipients

Abstract Background Bamlanivimab and casirivimab-imdevimab are authorized for emergency use treatment of mild-to-moderate COVID-19 in patients at high-risk for developing severe disease or hospitalization. Their safety and efficacy have not been specifically evaluated in solid organ transplant recipients. Methods We retrospectively reviewed solid organ transplant recipients who received monoclonal antibody infusion for COVID-19 at Mayo Clinic sites through January 23, 2021. Outcomes included emergency department visit, hospitalization, mortality, and allograft rejection. Results Seventy-three patients were treated, most commonly with bamlanivimab (75.3%). Median age was 59 years, 63% were male, and the median Charlson comorbidity index was 5. Transplant type included 41 kidney (56.2%), 13 liver (17.8%), 11 heart (15.1%), 4 kidney-pancreas (5.5%), 2 lung (2.7%), 1 heart-liver, and 1 pancreas. Eleven (15.1%) patients had an emergency department visit within 28 days of infusion, including 9 (12.3%) who were hospitalized for a median of 4 days. One patient required intensive care unit admission for a non-respiratory complication. No patients required mechanical ventilation, died, or experienced rejection. Ten adverse events occurred with one seeking medical evaluation. Hypertension was associated with hospital admission (p<.05) while other baseline characteristics were similar. Median time from symptom onset to antibody administration was 4 days in non-hospitalized patients compared to 6 days among hospitalized patients (p<.05). Conclusions Monoclonal antibody treatment has favorable outcomes with minimal adverse effects in solid organ transplant recipients with mild-to-moderate COVID-19. Earlier administration of monoclonal antibody therapies appears to be more efficacious.

Pilot study to examine the clinical utility of biofeedback in solid organ transplant.

2019 ◽  
Vol 7 (2) ◽  
pp. 127-139 ◽  
Author(s):  
Kristine McKenna ◽  
Lara Goodrich ◽  
Peter W. Forbes ◽  
Patricia Ibeziako
Keyword(s):  
Pilot Study ◽  
Clinical Utility ◽  
Organ Transplant ◽  
Solid Organ Transplant ◽  
Solid Organ
Sign in / Sign up

Export Citation Format

Share Document